Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Olaparib Plus Neratinib Shows Early Potential in HER2+ Ovarian Cancer

March 19th 2019

Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.

Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer

March 19th 2019

The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.

Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer

March 19th 2019

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer

March 18th 2019

Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.

Pembrolizumab/Bevacizumab Regimen Induces Durable Responses in Ovarian Cancer

March 18th 2019

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18th 2019

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

Dr. Moore on the Impact of the SOLO-1 Trial in Ovarian Cancer

March 18th 2019

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance

March 17th 2019

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

Repeat Use of PARP Inhibitors Could Be Effective Strategy in Ovarian Cancer

March 17th 2019

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

Dr. Coleman on the Effect of Age on Rucaparib Efficacy in Ovarian Cancer

March 17th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.

Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer

March 17th 2019

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer

March 8th 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

New Strategies and Novel Agents Transform Ovarian Cancer Into a Chronic Condition

March 7th 2019

The immediate future of clinical investigation in ovarian cancer is remarkably exciting, with a number of novel agents and combination strategies currently being examined in multiple clinical trials.

Dr. Campos Discusses Differences Between PARP Inhibitors in Recurrent Ovarian Cancer

March 5th 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.

Mirvetuximab Soravtansine Misses Primary Endpoint in Ovarian Cancer Trial

March 1st 2019

Mirvetuximab soravtansine did not improve progression-free survival compared with chemotherapy in patients with folate receptor alpha–positive, platinum-resistant ovarian cancer and in an overall patient population, missing the primary endpoint of the phase III FORWARD I trial.

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

March 1st 2019

The role of intraperitoneal chemotherapy in epithelial ovarian cancer has been a controversial subject for almost 3 decades; now, investigators are moving away from its use.

Dr. Grisham on MEK Inhibition in Low-Grade Serous Ovarian Cancer

February 27th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses MEK inhibition in the treatment of patients with low-grade serous ovarian cancer.

Dr. Landen on Molecular Subtypes of Ovarian Cancer

February 23rd 2019

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the molecular subtypes of ovarian cancer.

Dr. Eskander on Need for Biomarkers in Ovarian Cancer

February 21st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

New Agents Push the Envelope in Ovarian Cancer

February 10th 2019

Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.